These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3361 related items for PubMed ID: 25852263

  • 1. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y, Sugimoto K, Inui H, Fukusato T.
    World J Gastroenterol; 2015 Apr 07; 21(13):3777-85. PubMed ID: 25852263
    [Abstract] [Full Text] [Related]

  • 2. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
    Corey KE, Rinella ME.
    Dig Dis Sci; 2016 May 07; 61(5):1387-97. PubMed ID: 26942734
    [Abstract] [Full Text] [Related]

  • 3. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
    Ganesh S, Rustgi VK.
    Clin Liver Dis; 2016 May 07; 20(2):351-64. PubMed ID: 27063274
    [Abstract] [Full Text] [Related]

  • 4. Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence.
    Tang JT, Mao YM.
    J Dig Dis; 2017 Nov 07; 18(11):607-617. PubMed ID: 29106066
    [Abstract] [Full Text] [Related]

  • 5. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, Munda P, Trauner M.
    Dig Dis; 2015 Nov 07; 33(4):598-607. PubMed ID: 26159280
    [Abstract] [Full Text] [Related]

  • 6. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
    Imprialos K, Stavropoulos K, Bouloukou S, Kerpiniotis G, Karagiannis A, Doumas M.
    Curr Vasc Pharmacol; 2018 Nov 07; 16(3):276-288. PubMed ID: 28676020
    [Abstract] [Full Text] [Related]

  • 7. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
    Caldwell S.
    Clin Mol Hepatol; 2017 Jun 07; 23(2):103-108. PubMed ID: 28494529
    [Abstract] [Full Text] [Related]

  • 8. Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?
    Musso G, Anty R, Petta S.
    Curr Pharm Des; 2013 Jun 07; 19(29):5297-313. PubMed ID: 23394094
    [Abstract] [Full Text] [Related]

  • 9. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options.
    Milic S, Mikolasevic I, Krznaric-Zrnic I, Stanic M, Poropat G, Stimac D, Vlahovic-Palcevski V, Orlic L.
    Drug Des Devel Ther; 2015 Jun 07; 9():4835-45. PubMed ID: 26316717
    [Abstract] [Full Text] [Related]

  • 10. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Golabi P, Bush H, Younossi ZM.
    Clin Liver Dis; 2017 Nov 07; 21(4):739-753. PubMed ID: 28987260
    [Abstract] [Full Text] [Related]

  • 11. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
    Chen G, Ni Y, Nagata N, Xu L, Ota T.
    Int J Mol Sci; 2016 Aug 23; 17(9):. PubMed ID: 27563875
    [Abstract] [Full Text] [Related]

  • 12. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
    Ji HF, Sun Y, Shen L.
    Nutrition; 2014 Sep 23; 30(9):986-91. PubMed ID: 24976430
    [Abstract] [Full Text] [Related]

  • 13. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T, Japanese Society of Gastroenterology, Japan Society of Hepatology.
    J Gastroenterol; 2015 Apr 23; 50(4):364-77. PubMed ID: 25708290
    [Abstract] [Full Text] [Related]

  • 14. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G, Mikhailidis DP, Sahebkar A.
    Metabolism; 2019 Dec 23; 101():154001. PubMed ID: 31672448
    [Abstract] [Full Text] [Related]

  • 15. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y, Fukusato T.
    World J Gastroenterol; 2014 Nov 14; 20(42):15539-48. PubMed ID: 25400438
    [Abstract] [Full Text] [Related]

  • 16. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
    Gottlieb A, Mosthael W, Sowa JP, Canbay A.
    Digestion; 2019 Nov 14; 100(2):79-85. PubMed ID: 30537758
    [Abstract] [Full Text] [Related]

  • 17. [New pharmacological treatment options for nonalcoholic fatty liver disease].
    Stefan N.
    Internist (Berl); 2020 Jul 14; 61(7):759-765. PubMed ID: 32409850
    [Abstract] [Full Text] [Related]

  • 18. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
    Kelley NS.
    Metab Syndr Relat Disord; 2016 Nov 14; 14(9):417-430. PubMed ID: 27710160
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological management of nonalcoholic fatty liver disease.
    Barb D, Portillo-Sanchez P, Cusi K.
    Metabolism; 2016 Aug 14; 65(8):1183-95. PubMed ID: 27301803
    [Abstract] [Full Text] [Related]

  • 20. Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management.
    Başaranoğlu M, Örmeci N.
    Turk J Gastroenterol; 2014 Apr 14; 25(2):127-32. PubMed ID: 25003670
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 169.